RBD-IgG levels correlate with protection in Residents Facing
SARS-CoV-2 B.1.1.7 Outbreaks
H. Blain*, E. Tuaillon*, L. Gamon, A. Pisoni, S. Miot, V. Delpui, N.
Si-Mohamed, C. Niel, Y. Rolland, B. Montes, S. Groc, S. Rafasse, A.M.
Dupuy, N. Gros, D. Muriaux, M.C. Picot, J. Bousquet
* Both authors contributed equally to the manuscript
Authors’ full names, academic degrees, and affiliations: Hubert Blain,
MD, PhD,1 Edouard Tuaillon MD, PhD,2Lucie Gamon,3 Amandine Pisoni PhD,2Stéphanie Miot MD, PhD,1 Valentin Delpui,1 Nejm Si-Mohamed, 1 Clémence Niel,2 Yves Rolland MD, PhD,4 Brigitte
Montes PharmD, PhD2, Soraya Groc2,
Sophia Rafasse,5 Anne-Marie Dupuy MD,
PhD,6 Nathalie Gros PhD, 5 Delphine
Muriaux PhD,5 Marie-Christine Picot MD,
PhD,3 Jean Bousquet MD, PhD7
- Department of Internal Medicine and Geriatrics, MUSE University,
Montpellier, France.
- Laboratory of Virology, INSERM U 1058/EFS, University hospital,
Montpellier, France.
- Clinical research and epidemiology unit, University hospital,
Montpellier, France.
- Gérontopôle de Toulouse, INSERM 1027; Toulouse, France.
- CEMIPAI, University of Montpellier, UAR3725 CNRS, Montpellier, France,
and Institute of Research in Infectiology of Montpellier (IRIM),
University of Montpellier, UMR9004 CNRS, Montpellier, France.
- Biochemistry and hormonology laboratory, University hospital,
Montpellier, France
- Department of Dermatology and Allergy, Universitätsmedizin, Berlin,
Germany and University hospital, Montpellier, France.
Running head: Antibodies and BNT162b2 Effectiveness